A new life cycle for this death care company

(Full access for Members only)

A new life cycle for this death care company

24 June 2022

The company featured in this report is one of the leading death care companies in Western Europe. Once a darling of investors with its stock rising almost tenfold, management problems subsequently made the share price drop by 90%.

Following a change in leadership, the company is now heading towards a normalisation from 2023. Assuming it returns to its pre-crisis profitability, the stock would have a price/earnings ratio of about 4. This figure does not even incorporate the future growth potential now that the company has a competent, forward-looking management in place. It also doesn't count the undervalued assets that it keeps on its balance sheet, such as hundreds of residential properties, quite a few of which can be sold off.

The stock price is currently too low by a factor of 2-3, at least.

The second half of 2022 should bring not one, but two or three catalysts for a re-rating of the stock. This should be followed by many years of growth, increasing market share, and increasing profitability. As such, this stock could do what the price of its American counterpart (Service Corporation International) has done during the past decade, when it rose fivefold.

At a later stage, a bidder for the entire company is likely to appear on stage, as has already happened for comparable companies in other European countries.

This is a stock that combines value and growth in an interesting way. It's listed on one of Europe's largest stock exchanges and is currently going through a sell-off (like the rest of the market). The resulting current price level would then prove a lucky entry point.

Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.

l  Report updates

Not a Member yet? Sign up for a Membership.
Already a Member? Log into your account to download the report updates.

9 January 2023

Report Update (PDF - 0.5MB)

21 July 2022

Report Update (PDF - 0.1MB)

Most recent

Latest reports (for Members only)

Research Report Dr. Martens

Dr. Martens plc: marching towards turnaround

Successful, timeless brands don't come up for a discounted sale very often. Enter Dr. Martens – a true bargain for contrarian investors.

Telco stock with quintuple catalyst

Telco stock with quintuple catalyst

Will we soon see a wave of M&A among European telco companies? This telco stock, in particular, could shine.

Benefitting from France's ageing population

Benefitting from France's ageing population

Following the "ORPEA scandal" that rocked France's care home sector in 2022, this stock should emerge stronger than before.